Allogeneic transplantation: Peripheral blood vs. bone marrow

Current Opinion in Oncology

Volumn 24, Issue 2, 2012, Pages 191-196

  Bensinger, William I ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

allogeneic marrow transplants; allogeneic peripheral blood stem cells; filgrastim; graft versus host disease; leukemia

Indexed keywords

AVIDIN; BIOTIN; CYCLOSPORIN; METHOTREXATE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; CANADA; CD34 SELECTION; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; DONOR; ENGRAFTMENT; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMAGNETIC SEPARATION; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK; SIBLING; STEM CELL MOBILIZATION; T CELL DEPLETION; UNITED STATES; UNRELATED DONORS; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84857053579     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834f5c27     Document Type: Review

References (49)

1. Russell NH, Hunter A, Rogers S, et al. Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341:1482. (Pubitemid 23161485)
2. Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85:1413-1415.
3. Russell NH, Hunter AE. Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant 1994; 13:353-355. (Pubitemid 24116734)
4. Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995; 85:1659-1665.
5. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colonystimulating factor). Blood 1995; 85:1666-1672.
6. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85:1655-1658.
7. Bensinger WI, Clift RA, Anasetti C, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Stem Cells 1996; 14:90-105. (Pubitemid 26041424)
8. Majolino I, Aversa F, Bacigalupo A, et al. Allogeneic transplants of rhG-CSFmobilized peripheral blood stem cells (PBSC) from normal donors. Haematologica 1995; 80:40-43.
9. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospectivecomparison withmarrowtransplantation. Blood1996; 88:2794-2800. (Pubitemid 26327536)
10. Bensinger WI, Buckner CD, Shannon-Dorcy K, et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88:4132-4138. (Pubitemid 26399158)
11. Russell JA, Bowen T, Brown C, et al. Allogeneic blood cell transplants for haematological malignancy: Comparison of engraftment and graft-versus-host disease with bone marrow transplantation. Bone Marrow Transplant 1996; 17:703-708. (Pubitemid 26156301)
12. Przepiorka D, Anderlini P, Ippoliti C, et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997; 19:455-460. (Pubitemid 27102011)
13. Azevedo WM, Aranha FJP, Gouvea JV, et al. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematologic malignancies. Bone Marrow Transplant 1995; 16:647-653.
14. Anderlini P, Przepiorka D, Champlin R, et al. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88:2819-2825. (Pubitemid 26357361)
15. Korbling M, Champlin R. Peripheral blood progenitor cell transplantation: A replacement for marrow auto-or allografts. Stem Cells 1996; 14:185-195. (Pubitemid 26109200)
16. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95:3702-3709. (Pubitemid 30412840)
17. Gratwohl A, Passweg J, Baldomero H, et al. Blood and marrow transplantation activity in Europe 1997 (Special Report). Bone Marrow Transplant 1999; 24:231-245.
18. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: Trends over the past 5 years. Bone Marrow Transplant 2011; 46:485-501.
19. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with earlystage leukemia: A report from the Socié té Française de Greffe de Moelle. J Clin Oncol 2000; 18:537-571.
20. Heldal D, Tjonnfjord GE, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25:1129-1136. (Pubitemid 30345247)
21. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22:1145-1151. (Pubitemid 29021122)
22. Vigorito AC, Marques Junior JF, Aranha FJ, et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematologic malignancies: An update. Haematologica 2001; 86:665-666. (Pubitemid 32601115)
23. Mahmoud HK, Fahmy OA, Kamel A, et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24:355-358. (Pubitemid 29403439)
24. Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: A randomised trial. Lancet Oncol 2010; 11:331-338. Ten-year follow-up of EBMT study shows more GVHD but no adverse effects of disease-free or overall survival.
25. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100:761-767. (Pubitemid 34832598)
26. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 2000; 355:1231-1237. (Pubitemid 30184533)
27. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531. (Pubitemid 34925122)
28. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175-181. (Pubitemid 32064138)
29. Mielcarek M, Storer BE, Martin PJ et al. Transplantation of peripheral blood cells as compared with bone marrow from HLA-identical related donors is associated with superior long-term outcomes. Blood 2011; 118:abstract 319. Ten-year follow-up from the large U.S. trial showing continued protection against relapse with PBSC, still no differences in overall survival but better outcomes in patients with more advanced disease.
30. Storb R, Deeg HJ, Whitehead J, et al. Marrow transplantation for leukemia and aplastic anemia: Two controlled trials of a combination of methotrexate and cyclosporine versus cyclosporine alone or methotrexate alone for prophylaxis of acute graft-versus-host disease. Transplant Proc 1987; 19:2608-2613.
31. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80:1838-1845.
32. Bensinger W. Individual patient data meta-Analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: Indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 2006; 38:539-546. (Pubitemid 44509546)
33. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stemcell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-Analysis of nine randomized trials. J Clin Oncol 2005; 23:5074-5087.
34. Chang YJ, Weng CL, Sun LX, et al. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: A meta-Analysis based on time-to-event data from randomized controlled trials. Ann Hematol 2011. doi: 10.1007/s00277-011-1299-8. [Epub ahead of print] A meta-Analysis using reported time-to-event results finding faster engraftment, lower rates of relapse, more chronic GVHD but similar leukemia-free and overall survival.
35. Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94:455-464. (Pubitemid 29323860)
36. Anasetti C, Logan B, Lee SJ, et al. Increased incidence of chronic graftversus-host disease (GVHD) and no survival advantage with filgastrimmobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a phase III prospective randomized trial. Blood 2011; 118:abstract 1. Early results of a large North American trial comparing unrelated donor PBSCs with bone marrow showed more GVHD with PBSCs and no differences in overall survival. Relatively short follow-up of this trial limits these conclusions.
37. Urbano-Ispizua A, Solano C, Brunet S, et al. Allogeneic transplantation of selected CD34+ cells from peripheral blood: Experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. Bone Marrow Transplant 1998; 22:519-525. (Pubitemid 28445749)
38. Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the Blood and Marrow Transplant Clinical Trials Network protocol 0303. Biol Blood Marrow Transplant 2011; 17:1343-1351.
39. Jakubowski AA, Small TN, Kernan NA, et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011; 17:1335-1342.
40. Cornelissen JJ, van der HB, Petersen EJ, et al. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003; 31:855-864. (Pubitemid 37211369)
41. Isola L, Scigliano E, Fruchtman S. Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation. Biol Blood Marrow Transplant 2000; 6:428-433.
42. Serody JS, Sparks SD, Lin Y, et al. Comparison of granulocyte colonystimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLAmatched sibling transplantation. Biol Blood Marrow Transplant 2000; 6:434-440.
43. Couban S, Messner HA, Andreou P, et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: A study of 29 patients. Biol Blood Marrow Transplant 2000; 6:422-427.
44. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: Significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98:3186-3191.
45. Chang YJ, Huang XJ. Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: A comprehensive review. Clin Transplant 2011; 25:13-23. [Review]. A review of studies comparing filgrastim-stimulated bone marrow with unstimulated bone marrow or PBSC in both HLA identical and haploidentical studies. Faster engraftment with stimulated bone marrow, apparently less GVHD but study did not address the comparative rates of relapse.
46. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colonystimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4767-4773.
47. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720-5726.
48. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990-998.
49. Pidala J, Anasetti C, Kharfan-Dabaja MA, et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15:1415-1421. An interesting article integrating data on the risks and benefits of PBSCs compared to bone marrow to arrive at recommendations for treatment decisions.